Table 1 Baseline characteristics and pathological results according to biopsy grade group and PSA level.

From: Active surveillance in intermediate-risk prostate cancer with PSA 10–20 ng/mL: pathological outcome analysis of a population-level database

 

Grade group 1

Grade group 2

p*

 

PSA < 10 ng/mL (N = 15,301)

PSA 10–20 ng/mL (N = 1731)

p

PSA < 10 ng/mL (N = 8367)

PSA 10–20 ng/mL (N = 1149)

p

Age at diagnosis, year

59.7 ± 7.0

61.8 ± 6.8

<0.001

61.5 ± 6.9

62.9 ± 6.8

<0.001

<0.001

Race/ethnicity

  

<0.001

  

0.004

0.067

White

12,649 (82.7%)

1330 (76.8%)

 

6813 (81.4%)

889 (77.4%)

  

Black

1769 (11.5%)

259 (15.0%)

 

1038 (12.4%)

176 (15.3%)

  

Others/unknown

883 (5.8%)

142 (8.2%)

 

516 (6.2%)

84 (7.3%)

  

Clinical T stage

  

0.247

  

0.001

<0.001

T1

11,271 (73.7%)

1298 (75.0%)

 

5872 (70.2%)

860 (74.8%)

  

T2

4030 (26.3%)

433 (25.0%)

 

2495 (29.8%)

289 (25.2%)

  

PSA, ng/mL

5.1 ± 1.9

13.1 ± 2.7

<0.001

5.4 ± 1.9

12.9 ± 2.6

<0.001

<0.001

% Positive cores

17.1 ± 8.0

16.6 ± 8.1

0.026

19.2 ± 7.7

18.9 ± 7.9

0.226

<0.001

Insurance

  

<0.001

  

<0.001

0.702

Insured

14,723 (96.2%)

1619 (93.5%)

 

8072 (96.5%)

1060 (92.3%)

  

Medicaid

422 (2.8%)

85 (4.9%)

 

204 (2.4%)

69 (6.0%)

  

Uninsured

156 (1.0%)

27 (1.6%)

 

91 (1.1%)

20 (1.7%)

  

Marital status

  

<0.001

  

<0.001

<0.001

Married

12,729 (83.2%)

1341 (77.5%)

 

6783 (81.1%)

874 (76.1%)

  

Single

2572 (16.8%)

390 (22.5%)

 

1584 (18.9%)

275 (23.9%)

  

Pathologic upgrading at RP

  

<0.001

  

<0.001

<0.001

No

14,410 (94.2%)

1530 (88.4%)

 

7002 (83.7%)

875 (76.2%)

  

Yes

891 (5.8%)

201 (11.6%)

 

1365 (16.3%)

274 (23.8%)

  

Pathologic upstaging at RP

  

<0.001

  

<0.001

<0.001

No

14,149 (92.5%)

1478 (85.4%)

 

6969 (83.3%)

828 (72.1%)

  

Yes

1152 (7.5%)

253 (14.6%)

 

1398 (16.7%)

321 (27.9%)

  

Adverse pathology

  

<0.001

  

<0.001

<0.001

No

13,470 (88.0%)

1349 (77.9%)

 

6027 (72.0%)

672 (58.5%)

  

Yes

1831 (12.0%)

382 (22.1%)

 

2340 (28.0%)

477 (41.5%)

  
  1. PSA prostate-specific antigen, RP radical prostatectomy.
  2. *p value between grade groups.
Back to article page